Regencell Bioscience (NASDAQ:RGC) Trading Up 5.5% – Time to Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares shot up 5.5% on Wednesday . The company traded as high as $6.75 and last traded at $6.2780. Approximately 160,941 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 312,093 shares. The stock had previously closed at $5.95.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The firm has a 50 day moving average of $19.10 and a 200-day moving average of $24.91.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new position in Regencell Bioscience during the second quarter valued at $1,701,000. BNP Paribas Financial Markets purchased a new stake in Regencell Bioscience in the 2nd quarter worth $768,000. XTX Topco Ltd purchased a new stake in Regencell Bioscience in the 3rd quarter worth $598,000. Vident Advisory LLC boosted its holdings in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the last quarter. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.